Mark James Litton
CIK 1604834 · PRESIDENT and CEO · last filed 2026-04-13
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$478.6K
Companies
4
Total Filings
46
Lifetime Open-Market Net
-$5.65M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LONA | PRESIDENT and CEO | 58,582 | $8.17 | $478.6K | -$27.7K | 2 | 2026-04-13 |
| LeonaBio, Inc. (ATHA) Delisted | President and CEO | 44,070 | $6.92 | $305.0K | -$91.6K | 17 | 2026-01-05 |
| ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | See Remarks | — | $64.97 | — | $0 | 2 | 2019-02-08 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Chief Business Officer | 132,663 | — | — | -$5.53M | 21 | 2018-06-05 |
Recent Filings · Page 3 of 5
46 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-19 | LeonaBio, Inc. (ATHA) Delisted | Mixed | +51,307 | $80.6K | EDGAR |
| 2021-02-22 | LeonaBio, Inc. (ATHA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-09-22 | LeonaBio, Inc. (ATHA) Delisted | Conv (C) | +32,815 | $0 | EDGAR |
| 2019-02-08 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-08-08 | ALPINE IMMUNE SCIENCES, INC. (ALPN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-05 | ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Mixed | — | -$382.9K | EDGAR |
| 2018-02-21 | ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-11-15 | ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Mixed | — | -$151.2K | EDGAR |
| 2017-10-18 | ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Mixed | — | -$176.4K | EDGAR |
| 2017-01-31 | ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.